ReviewNature medicine2018
Mechanisms of NAFLD development and therapeutic strategies.
Review in Nature medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 2,366 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Relationship Between the Development of Impaired Glucose Tolerance, the Phenotype of CFLD, and the Risk of Liver Fibrosis
Evaluation of Lipid Profile in Different Grades of Non-alcoholic Fatty Liver Disease Diagnosed by Ultrasound
Fetuin-A, a Promising Serum Biomarker for Diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD)
Korean Health Screening-Based Metabolic Dysfunction-Associated Steatotic Liver Disease Registry: A Retrospective Multicenter Cross-Sectional Study (K-MASLD Registry)
Who cites it
2,366 citing papers in PubMed, 6 syntheses or guidelines pooled it, 4,074 citations in OpenAlex.
- Clinical Practice Guidelines for Adult MASLD in Bosnia and Herzegovina: National Recommendations for Diagnosis, Risk Stratification, and Treatment.Acta medica academica · 2026Guideline
- Clinical evidence of semaglutide for metabolic dysfunction-associated steatotic liver disease (MASLD): An updated meta-analysis.British journal of clinical pharmacology · 2026Pooled it
- Efficacy of Empagliflozin on Liver Enzymes, Lipid Profile and BMI in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-Analysis.Endocrinology, diabetes & metabolism · 2026Pooled it
- Therapeutic Effects of Glucagon-like Peptide-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: A Systematic Review.International journal of molecular sciences · 2026Pooled it
- Integrative genetic and liver transcriptomic analyses identify TRIB1AL as a target for steatotic liver disease.The Journal of clinical endocrinology and metabolism · 2026Pooled it
- Effects of curcumin on anthropometric measurements in nonalcoholic fatty liver disease: An umbrella meta-analysis study.Medicine · 2026Pooled it
- Pistacia atlantica sub. Kurdica can improve insulin resistance in patients with non-alcoholic fatty liver disease: a randomized clinical trial.BMC complementary medicine and therapies · 2026Trial
- Feasibility study of a behavioral lifestyle intervention for Hispanic/Latino patients with metabolic dysfunction-associated steatotic liver disease.BMC public health · 2026Trial
- Metabolic profiling of healthy vs. syndrome-associated obesity and effects of six-month metformin therapy.Acta diabetologica · 2026 · on this mapTrial
- Protective effects ofRedox report : communications in free radical research · 2026Article
- Hepatic steatosis affects the outcome of anti-tuberculosis treatment in pulmonary tuberculosis patients.Journal of clinical tuberculosis and other mycobacterial diseases · 2026Article
- The role of FGF19-FGFR4 signaling pathway in liver health and disease: Guardian or destroyer.Genes & diseases · 2026Review
- Global Landscape and Thematic Evolution of Selective GLP-1 Receptor Agonists and GLP-1-Based Multi-Receptor Agonists in Type 2 Diabetes Mellitus: A Bibliometric Analysis.Endocrinology, diabetes & metabolism · 2026Review
- Review Article: Fibrosis Reversal in Metabolic Dysfunction-Associated Steatohepatitis-The Promise of Emerging Therapeutics.Alimentary pharmacology & therapeutics · 2026Review
- Altered cholangiocyte subsets with neural pathway enrichment in metabolic dysfunction-associated steatotic liver disease.Internal and emergency medicine · 2026Article
- Ursolic acid ameliorates metabolic dysfunction-associated fatty liver disease by regulating the NOX4/ROS/NLRP3 pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Apigenin attenuates MASLD progression by suppressing lipogenesis and macrophage M1-like inflammatory activation: involvement of SMAD4-associated signaling.Journal of molecular histology · 2026Article
- Pomegranate seed oil attenuates palmitic acid-induced hepatic injury through modulation of oxidative stress: insights from GC-Q-TOF-MS-based metabolomics.Journal of the science of food and agriculture · 2026Article
- Triglyceride-to-HDL Cholesterol Ratio is Associated with Hepatic Steatosis but not Fibrosis in Patients with Severe Obesity: A Cross-Sectional Study.Obesity surgery · 2026Article
- ZRSR1 protects against obesity-associated hepatic lipogenesis independent of minor intron splicing.Life metabolism · 2026Article
2,306 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
Abstract
There has been a rise in the prevalence of nonalcoholic fatty liver disease (NAFLD), paralleling a worldwide increase in diabetes and metabolic syndrome. NAFLD, a continuum of liver abnormalities from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH), has a variable course but can lead to cirrhosis and liver cancer. Here we review the pathogenic and clinical features of NAFLD, its major comorbidities, clinical progression and risk of complications and in vitro and animal models of NAFLD enabling refinement of therapeutic targets that can accelerate drug development. We also discuss evolving principles of clinical trial design to evaluate drug efficacy and the emerging targets for drug development that involve either single agents or combination therapies intended to arrest or reverse disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.